Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$4.77M, compared with -$1.9M a year earlier. Trailing-twelve-month other income / expenses was -$1.19M. Over 3 fiscal years it compounded at -73.2% a year.

Context

  • Other income / expenses amounted to 1.0% of revenue in FY2025, down 4.4 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$4.77M or moves back toward the trailing-twelve-month quarterly average of -$296.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.77M+55.2% QoQ
Last fiscal yearDec 2025
$1.68M-86.3% YoY
LTMMar 2026
-$1.19M+33.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-150.7%——
1 year-86.3%——
3-year CAGR-73.2%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
1.68M USD
Year-over-year change
-86.3%

Other Income / Expenses vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.1% is the 2nd highest of 10, against a peer median of -42.1%.
  • Other income / expenses amounts to 0.8% of revenue for DNA, versus a peer median of 27.0%.
DNA Competitors
Other Income / Expenses for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARVNArvinas, Inc.LTM Mar 2026$28.7M USD-42.1%+178.1%32.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$19.31M USD-71.4%—29.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$15.24M USD+46.9%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$11.63M USD-10.2%——
REPLReplimune Group, Inc.LTM Dec 2025$10.64M USD-20.2%+276.2%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$8.6M USD-33.8%+20.0%2.3%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-$1.19M USD+33.1%-73.2%0.8%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$15.34M USD-85.0%—19.2%
VALNValneva SELTM Mar 2026-€38.24M EUR-120.8%—24.5%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$232.58M USD-785.1%—111.4%
Peer median (excluding DNA) —-42.1%+178.1%27.0%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.